The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Evaluating atezolizumab in early-stage and limited-stage lung cancer
Shankar Siva, PhD, MBBS, FRANZCR, Peter MacCallum Cancer Centre, Melbourne, Australia, provides an overview of two randomized trials assessing the role of atezolizumab in curative-intent lung cancer settings. The Phase III SWOG/NRG S1914 trial (NCT04214262) found no survival benefit when atezolizumab was added to stereotactic body radiation therapy in high-risk, early-stage non-small cell lung cancer (NSCLC), with increased toxicity observed. Separately, a Phase II study (NCT03540420) in limited-stage small cell lung cancer (LS-SCLC) showed no progression-free or overall survival advantage when atezolizumab was administered following chemoradiotherapy. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
